Abstract
Neurobehavioural comorbidities have a detrimental effect on the quality of life of people with epilepsy, yet tracking their impact is challenging as behaviour may vary with seizures and anti-seizure medication side effects. Smartphones have the potential to monitor day-to-day neurobehavioural patterns objectively. We present the case of a man in his late twenties with refractory focal epilepsy in whom we ascertained the effects of ASMs withdrawal and a focal-to-bilateral tonic-clonic convulsion on his touchscreen interactions. Using a dedicated app, we recorded over 185 days, the timestamps of 718,357 interactions. We divided the various smartphone behaviours according to the next-interval dynamics of the interactions by using a joint interval distribution (JID). We analysed JIDs during two ASM load transitions: before versus during tapering and restarting medication versus tapering. Cluster-based permutation testing revealed significant differences, with accelerated next-interval dynamics during tapering and a reversal upon medication restart. We also compared the JID of the fbTCS day to the average of the three days before, showing markedly slower next-interval dynamics on the day of the convulsion. This suggests that smartphone interactions’ temporal dynamics may help monitor neurobehavioural comorbidities in epilepsy.
Competing Interest Statement
A.G. is a cofounder of QuantActions AG, Zurich, Switzerland which focus on converting smartphone touchscreen interactions to mental health indicators. Software and data services from QuantActions were used to monitor smartphone activity. R.D.T. reports personal fees from UCB, Theravarance, Novartis, Zogenix, Arvelle, Angelini, Medtronic, and NewLife Wearables.
Funding Statement
This study was funded by Health-Holland, Top Sector Life Sciences & Health Netherlands Organization for Health Research and Development (ZonMW) [Brain@home, Project number: 114025101]. R.D.T. is supported by the Christelijke Vereniging voor de Verpleging van Lijders aan Epilepsie, and by research .grants from the Dutch National Epilepsy Fund (EpilepsieNL), This study leveraged the support to A.G. by a research grant from Velux Stiftung (Project number: 1283).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Medical Ethics Committee (Leiden-Den Haag-Delft - P19.088) approved the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.